Parkinson's Disease and α-Synuclein Expression

被引:140
|
作者
Devine, Michael J. [1 ]
Gwinn, Katrina [2 ]
Singleton, Andrew [3 ]
Hardy, John [1 ]
机构
[1] UCL Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] NIA, NIH, Bethesda, MD 20892 USA
基金
英国惠康基金; 英国医学研究理事会;
关键词
Parkinsonism; genetics; alpha-synuclein; MULTIPLE SYSTEM ATROPHY; LEWY BODY; IN-VIVO; SNCA DUPLICATION; GENE DUPLICATION; MOUSE MODEL; NEURODEGENERATIVE DISEASE; DOPAMINERGIC-NEURONS; LOCUS TRIPLICATION; MESSENGER-RNA;
D O I
10.1002/mds.23948
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Genetic studies of Parkinson's disease over the last decade or more have revolutionized our understanding of this condition. alpha-Synuclein was the first gene to be linked to Parkinson's disease, and is arguably the most important: the protein is the principal constituent of Lewy bodies, and variation at its locus is the major genetic risk factor for sporadic disease. Intriguingly, duplications and triplications of the locus, as well as point mutations, cause familial disease. Therefore, subtle alterations of alpha-synuclein expression can manifest with a dramatic phenotype. We outline the clinical impact of alpha-synuclein locus multiplications, and the implications that this has for Parkinson's disease pathogenesis. Finally, we discuss potential strategies for disease-modifying therapies for this currently incurable disorder. (C) 2011 Movement Disorder Society
引用
收藏
页码:2160 / 2168
页数:9
相关论文
共 50 条
  • [41] Expression of alpha-synuclein isoforms in familial and sporadic Parkinson's disease
    Mutez, E.
    Larvor, L.
    Duflot, A.
    Vanbesien, C.
    Mouroux, V.
    Destee, A.
    Chartier-Harlin, M. -C.
    MOVEMENT DISORDERS, 2011, 26 : S314 - S314
  • [42] The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson’s disease
    Jihua Shi
    Yiran Wang
    Dan Chen
    Xue Xu
    Wenbin Li
    Kai Li
    Jing He
    Wen Su
    Qingfeng Luo
    Applied Microbiology and Biotechnology, 2023, 107 : 1917 - 1929
  • [43] Familial Parkinson's disease α-synuclein and parkin
    Mizuno, Y
    Hattori, N
    Kitada, T
    Matsumine, H
    Mori, H
    Shimura, H
    Kubo, S
    Kobayashi, H
    Asakawa, S
    Minoshima, S
    Shimizu, N
    PARKINSON'S DISEASE, 2001, 86 : 13 - 21
  • [44] α-Synuclein in Parkinson's disease: causal or bystander?
    Riederer, Peter
    Berg, Daniela
    Casadei, Nicolas
    Cheng, Fubo
    Classen, Joseph
    Dresel, Christian
    Jost, Wolfgang
    Krueger, Rejko
    Mueller, Thomas
    Reichmann, Heinz
    Riess, Olaf
    Storch, Alexander
    Strobel, Sabrina
    van Eimeren, Thilo
    Voelker, Hans-Ullrich
    Winkler, Juergen
    Winklhofer, Konstanze F.
    Wuellner, Ullrich
    Zunke, Friederike
    Monoranu, Camelia-Maria
    JOURNAL OF NEURAL TRANSMISSION, 2019, 126 (07) : 815 - 840
  • [45] α-Synuclein in Parkinson's disease and advances in detection
    Chen, Rong
    Gu, Xuan
    Wang, Xiaoying
    CLINICA CHIMICA ACTA, 2022, 529 : 76 - 86
  • [46] Immunological features of α-synuclein in Parkinson's disease
    Roodveldt, Cintia
    Christodoulou, John
    Dobson, Christopher M.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2008, 12 (5B) : 1820 - 1829
  • [47] Environmental toxins and α-synuclein in Parkinson’s disease
    Yanying Liu
    Hui Yang
    Molecular Neurobiology, 2005, 31 : 273 - 282
  • [48] Alpha-synuclein and Parkinson's disease
    Golbe, LI
    MOVEMENT DISORDERS, 1999, 14 (01) : 6 - 9
  • [49] Parkinson's disease biomarkers based on α-synuclein
    Fayyad, Muneera
    Salim, Safa
    Majbour, Nour
    Erskine, Daniel
    Stoops, Erik
    Mollenhauer, Brit
    El-Agnaf, Omar M. A.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 (05) : 626 - 636
  • [50] Biomarkers and the Role of α-Synuclein in Parkinson's Disease
    Du, Tingting
    Wang, Le
    Liu, Weijin
    Zhu, Guanyu
    Chen, Yingchuan
    Zhang, Jianguo
    FRONTIERS IN AGING NEUROSCIENCE, 2021, 13